PMID- 37580277
OWN - NLM
STAT- MEDLINE
DCOM- 20230830
LR  - 20230830
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 45
IP  - 8
DP  - 2023 Aug 23
TI  - [Efficacy and safety evaluation of immunotherapy combined with targeted therapy 
      as second-line treatment in patients with metastatic non-clear cell renal cell 
      carcinoma].
PG  - 704-708
LID - 10.3760/cma.j.cn112152-20220330-00220 [doi]
AB  - Objective: This study aimed to evaluate the efficacy and safety of programmed 
      death-1 (PD-1) inhibitor combined tyrosine kinase inhibitor (TKI) therapy versus 
      TKI monotherapy as the second-line regimen for patients with metastatic non-clear 
      cell renal carcinoma (nccRCC) who failed first-line TKI therapy. Methods: The 
      clinicopathological data of 67 patients with metastatic nccRCC who failed 
      first-line TKI therapy between October 2011 and September 2020 were 
      retrospectively analyzed, including 22 patients who received TKI monotherapy and 
      45 patients who received TKI plus PD-1 inhibitor as the second-line therapy. The 
      efficacy was assessed according to Response Evaluation Criteria in Solid Tumors 
      version 1.0/1.1 (RECIST 1.0/1.1), the Kaplan-Meier method was used to plot the 
      survival curves, and the Log rank test was used to analyze the differences in the 
      survival between the two groups. Treatment-related adverse events (AEs) after 
      treatment were observed in both groups. Results: The overall objective response 
      rate (ORR) and disease control rate (DCR) were 37.3% (25/67) and 56.7% (38/67), 
      respectively. The overall second-line progression-free survival (PFS) was 7.7 
      months and Overall Survival (OS) was 25.2 months. The ORR and DCR of patients in 
      the combination therapy group were 48.9% (22/45) and 71.1% (32/45), respectively, 
      which were significantly improved compared with the TKI monotherapy group [13.6% 
      (3/22) and 27.3% (6/22), respectively] (P=0.007 and P=0.001, respectively). The 
      median PFS of 9.2 months for second-line treatment was longer in patients in the 
      combination therapy group than in the TKI monotherapy group (5.2 months, 
      P=0.001), but the median OS was not statistically different between the two 
      groups (28.2 months vs 20.8 months, P=0.068). Common treatment-related AEs 
      included hypertension, diarrhea, fatigue, stomatitis, hand-foot syndrome, and 
      hypothyroidism. The incidence of hypothyroidism was higher in the combination 
      therapy group [40.0% (18/45)] than in the TKI monotherapy group [22.7% (5/22), 
      P=0.044]; the incidence of other treatment-related AEs between the two groups 
      were not statistically significant (all P>0.05). Conclusion: Immune-targeted 
      combination therapy was more effective than TKI monotherapy alone and was well 
      tolerated in the treatment of metastatic nccRCC patients who failed first-line 
      TKIs.
FAU - Wang, J
AU  - Wang J
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Wei, W S
AU  - Wei WS
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Jiang, L J
AU  - Jiang LJ
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Zhang, Z L
AU  - Zhang ZL
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Guo, S J
AU  - Guo SJ
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Han, H
AU  - Han H
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Zhou, F J
AU  - Zhou FJ
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
FAU - Dong, P
AU  - Dong P
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, 
      China.
LA  - chi
GR  - 2021B1515020077/Natural Science Foundation for Distinguished Young Scholars of 
      Guangdong Province/
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - Clear-cell metastatic renal cell carcinoma
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/drug therapy
MH  - Immunotherapy/adverse effects
MH  - *Kidney Neoplasms/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Immunotherapy
OT  - Programmed death-1 inhibitor
OT  - Renal neoplasms, non-clear cell
OT  - Second-line therapy
OT  - Tyrosine kinase inhibitor
EDAT- 2023/08/15 00:42
MHDA- 2023/08/16 06:43
CRDT- 2023/08/14 21:59
PHST- 2023/08/16 06:43 [medline]
PHST- 2023/08/15 00:42 [pubmed]
PHST- 2023/08/14 21:59 [entrez]
AID - 10.3760/cma.j.cn112152-20220330-00220 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2023 Aug 23;45(8):704-708. doi: 
      10.3760/cma.j.cn112152-20220330-00220.